STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

300204

CNE100001237

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6.3 ^CNY	-2.17%		+11.50%	-37.99%

Apr. 24	Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 25	Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Staidson BioPharmaceuticals Co., Ltd.(XSEC:300204) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Staidson (Beijing) BioPharmaceuticals Co., Ltd.(XSEC:300204) added to S&P Global BMI Index

Latest news about Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Staidson BioPharmaceuticals Co., Ltd.(XSEC:300204) added to S&P Global BMI Index	23-09-18	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Staidson BioPharmaceuticals Co., Ltd. amended terms of the transaction	23-06-25	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Staidson Pharma Unit Gets FDA's Emergency Use Authorization for COVID-19 Drug; Shares Soar 18%	23-04-06	MT
Review Into Staidson Biopharma Unit's Anti-COVID-19 Drug Shows Safety, Tolerability in Patients; Shares Jump 5%	23-02-17	MT
Staidson's Respiratory Drug Shows Safety in Trial	23-01-23	MT
Chinese Shares Finish Lower; Staidson Falls 8% After Signing R&D Deal With Germany’s InflaRx	22-12-23	MT
Staidson Forms R&D Deal With Germany’s InflaRx	22-12-22	MT
Staidson BioPharmaceuticals Co., Ltd. announced that it expects to receive CNY 580 million in funding	22-12-21	CI
Inflarx Gmbh and Staidson Biopharmaceuticals Co., Ltd Enters into Third Addendum to the Co-Development Agreement	22-12-21	CI
InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson BioPharmaceuticals Co., Ltd.	22-12-20	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-18	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-18	CI
Chinese Shares End Lower; Pharmaceutical Stlocks Suffer Huge Losses After WuXi Biologics' US Sanction	22-02-11	MT
Staidson Beijing Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-11	CI
Staidson Beijing Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-23	CI
Staidson BioPharmaceuticals Co., Ltd. Announces Election of Board of Directors	21-08-12	CI
Staidson Beijing Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-19	CI
Staidson Beijing Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-29	CI

Chart Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Duration

Period

Chart Staidson (Beijing) BioPharmaceuticals Co., Ltd.

More charts

Staidson (Beijing) Biopharmaceuticals Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of innovative therapeutic medicine with independent intellectual property rights including protein medicine, genetic medicine and chemical medicine, among others. The Companyâs products include mouse nerve growth factor for injection, which are applied in the neuroprotection and treatment of nerve injuries, as well as polyethylene glycol electrolyte powders, which are applied in the bowel cleansing and treatment of constipation. The Company mainly distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.	-37.99%	415M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B